Physician profile
Natalia Johnson
NPI 1740810928
$879.53
in general payments reported to CMS, 2019-2025
13 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $144 · 2024: $190 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.53 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $200.00 | 2024-2025 | Farxiga |
| Abbvie INC. | $170.95 | 2022 | |
| Boston Scientific Corporation | $116.72 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Astellas Pharma US INC | $90.00 | 2024 | |
| Mayne Pharma Commercial LLC | $74.10 | 2022 | |
| Medtronic, INC. | $54.98 | 2022 | |
| Myovant Sciences INC. | $42.60 | 2022 | |
| Currax Pharmaceuticals LLC | $27.50 | 2022 | |
| Daiichi Sankyo INC. | $26.81 | 2023 | Injectafer |
| Evofem Biosciences, INC. | $22.64 | 2022 | |
| Mylan Pharmaceuticals INC. | $21.08 | 2022 | |
| Organon LLC | $17.73 | 2022 | |
| Antares Pharma, INC. | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.